Several other research firms have also weighed in on PFE. Vetr lowered Pfizer from a buy rating to a hold rating and set a $37.98 price objective on the stock. in a research note on Monday, January 15th. Zacks Investment Research raised Pfizer from a hold rating to a buy rating and set a $41.00 price objective on the stock in a research note on Wednesday, January 17th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a buy rating in a research note on Wednesday, January 24th. SunTrust Banks reaffirmed a hold rating and issued a $40.00 price objective (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the company a neutral rating in a research note on Tuesday, January 30th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $40.08.
PFE opened at $35.71 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98. The stock has a market capitalization of $212.46 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89. Pfizer has a 12 month low of $35.64 and a 12 month high of $35.80.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.
In other Pfizer news, CEO Ian C. Read sold 132,312 shares of the company’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total value of $1,515,973.68. The disclosure for this sale can be found here. Insiders have sold a total of 380,349 shares of company stock worth $13,829,340 over the last three months. 0.06% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Ballew Advisors Inc bought a new stake in shares of Pfizer in the 1st quarter valued at approximately $102,000. Earnest Partners LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $105,000. First Dallas Securities Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $118,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $126,000. 71.65% of the stock is currently owned by institutional investors.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.